The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
== Polymerization == Polypropylene glycol is produced by ring-opening polymerization of propylene oxide. The initiator is an alcohol and the catalyst a base, usually potassium hydroxide. When the initiator is ethylene glycol or water the polymer is linear. With a multifunctional initiator like glycerine, pentaerythritol or sorbitol the polymer branches out.
Mixed ligand complexes are common for amino acids. Well known examples include [Co(en)2(glycinate)]2+, where en (ethylenediamine) is a spectator ligand. In the area of organometallic complexes, one example is the half-sandwich complex Cp*Ir(κ3-methionine).
Two examples of this are the US Navy's Grumman E-2 Hawkeye and the US Air Force's Boeing E-3 Sentry. Both were used in command and control area of operations. These systems provided essential communications links between air, ground, and naval forces. It is one of several reasons coalition forces dominated the air war. American-made color photocopiers were used to produce some of Iraq's battle plans. Some of the copiers contained concealed high-tech transmitters that revealed their positions to American electronic warfare aircraft, leading to more precise bombings.
In men and women, the sole requirement for being considered a dwarf is having an adult height of 147 cm (4 ft 10 in) or less, and it is almost always sub-classified with respect to the underlying condition that is the cause of the short stature. Dwarfism is usually caused by a genetic variant; achondroplasia is caused by a mutation on chromosome 4. If dwarfism is caused by a medical disorder, the person is referred to by the underlying diagnosed disorder. Disorders causing dwarfism are often classified by proportionality. Disproportionate dwarfism describes disorders that cause unusual proportions of the body parts, while proportionate dwarfism results in a generally uniform stunting of the body. Disorders that cause dwarfism may be classified according to one of hundreds of names, which are usually permutations of the following roots:
Sources: en.wikipedia.org
== Pathology == When initially identified, camptocormia was classified as a psychogenic disease. Although the condition is sometimes a psychogenic manifestation, camptocormia typically originates from either muscular or neurological diseases. However, due to the wide variety of pathologies resulting in camptocormia, there is no singular cause that is most influential for the condition.
1993/2685) Walsgrave Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2686) Industrial Tribunals (Constitution and Rules of Procedure) Regulations 1993 (S.I. 1993/2687) Industrial Tribunals (Constitution and Rules of Procedure) (Scotland) Regulations 1993 (S.I. 1993/2688) Disclosure of Interests in Shares (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2689) Prior Rights of Surviving Spouse (Scotland) S.I. 1993/2690) Central Manchester National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2691) Lancaster Acute Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2692) Lancaster Priority Services National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2693) Lifecare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2694) Lifespan Health Care Cambridge National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2695) Lincolnshire Ambulance and Health Transport Service National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2696) Mayday Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2697) Weights and Measures Act 1985 Commencement (Revocation) Order 1993 (S.I. 1993/2698)
==== TPN-based cholestasis ==== Total parenteral nutrition (TPN) is given to patients with intestinal failure or a variety of other gastrointestinal problems. Under normal settings, TPN causes a slight elevation of ALP levels. However, this does not indicate cholestasis alone. In the case of TPN-induced cholestasis, there is an excessive elevation of ALP, gamma-glutamyltransferase (GGT), and conjugated bilirubin. Without appropriate intervention, symptoms can quickly exacerbate, leading to liver cirrhosis and failure. Cholestasis arising from TPN has a diverse range of causes, including toxicity to TPN components, underlying disorders, or a lack of enteral nutrition. Without enteral food consumption, gallbladder function is greatly inhibited, leading to gallstone formation, subsequent blockage, and eventually cholestasis. Cholestasis resulting from TPN may also be a result of reduced bile flow from portal endotoxins. With TPN, there is a reduction in gastrointestinal motility, immunity, with an increase in permeability. These changes facilitate bacteria growth and increase the amount of circulating endotoxin. Moreover, given that patients using TPN often have underlying health problems, drugs being used with known liver toxicity may also cause cholestasis. Lipids in TPN may cause cholestasis and liver damage by overwhelming clearage mechanisms. Intravenous glucose can also cause cholestasis as a result of increased fatty acid synthesis and decreased breakdown, which facilitates the accumulation of fats.
5 August – George Herd, 88, Scottish football player (Sunderland, national team) and manager (Queen of the South). 6 August – Ron Bain, 79, Scottish actor (Naked Video, A Kick Up the Eighties) and director (I, Lovett). (death announced on this date) Bobby Thomson, 87, Scottish footballer (Aston Villa, Birmingham City). 9 August – Brian Marjoribanks, 82, Scottish footballer (Hibernian), actor and broadcaster (BBC Scotland). 12 August – Alex Kinninmouth, 82, Scottish footballer (Dundee, Dunfermline Athletic, Forfar Athletic). (death announced on this date) 2 September – Mick Cullen, 93, Scottish footballer (Luton Town, Grimsby Town, national team). 3 September – Flora Fraser, 21st Lady Saltoun, 93, Scottish peer, member of the House of Lords (1979–2014). 6 September – Ron Yeats, 86, Scottish footballer (Dundee United, Liverpool, Tranmere Rovers). 17 September – Kenny Hyslop, 73, Scottish drummer (Slik, Zones, Simple Minds). (death announced on this date) 18 September – Sam Malcolmson, 77, Scottish-born New Zealand footballer (Queen of the South, Albion Rovers, national team). 10 October – Peter Cormack, 78, Scottish football player (Liverpool, national team) and manager (Partick Thistle). 12 October Jackmaster, 38, Scottish DJ and record producer. Alex Salmond, 69, politician, first minister (2007–2014). 13 October – Jim Liddle, 66, Scottish footballer (Forfar Athletic, Cowdenbeath, Hamilton Academical). 22 October – Jim McColl, 89, Scottish horticulturalist and television presenter (Beechgrove). Myra McFadyen, 68, Scottish actress (Made of Honor, Mamma Mia!, Emma).
Graphite oxides absorb moisture in proportion to humidity and swell in liquid water. The amount of water absorbed by graphite oxides depends on the particular synthesis method and shows a strong temperature dependence. Brodie graphite oxide selectively absorbs methanol from water/methanol mixtures in a certain range of methanol concentrations. Membranes prepared from graphite oxides (recently more often called "graphene oxide" membranes) are vacuum tight and impermeable to nitrogen and oxygen, but are permeable to water vapors. The membranes are also impermeable to "substances of lower molecular weight". Permeation of graphite and graphene oxide membranes by polar solvents is possible due to swelling of the graphite oxide structure. The membranes in swelled state are also permeable by gases, e.g. helium. Graphene oxide sheets are chemically reactive in liquid water, leading them to acquire a small negative charge. The interlayer distance of dried graphite oxides was reported as ~6–7 Å but in liquid water it increases up to 11–13 Å at room temperature. The lattice expansion becomes stronger at lower temperatures. The inter-layer distance in diluted NaOH reached infinity, resulting in dispersion of graphite oxide into single-layered graphene oxide sheets in solution. Graphite oxide can be used as a cation exchange membrane for materials such as KCl, HCl, CaCl2, MgCl2, BaCl2 solutions. The membranes were permeable by large alkali ions as they are able to penetrate between graphene oxide layers.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.